{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:31:13Z","timestamp":1790242273342,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3171,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1038\/sj.mt.6300363","type":"journal-article","created":{"date-parts":[[2007,12,11]],"date-time":"2007-12-11T10:43:59Z","timestamp":1197369839000},"page":"244-251","source":"Crossref","is-referenced-by-count":77,"title":["Virotherapy of Ovarian Cancer With Polymer-cloaked Adenovirus Retargeted to the Epidermal Growth Factor Receptor"],"prefix":"10.1016","volume":"16","author":[{"given":"Joanne","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Subr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Ulbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard W","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.mt.6300363_bib1","series-title":"UK Ovarian cancer statistics, 2002","author":"CRUK","year":"2007"},{"key":"10.1038\/sj.mt.6300363_bib2","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.mt.6300363_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1038\/sj.mt.6300363_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00273393","article-title":"Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group","volume":"18","author":"DeGregorio","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1038\/sj.mt.6300363_bib5","first-page":"1055","article-title":"Comparison of the iv and ip routes of administration of cisplatin in dogs","volume":"65","author":"Pretorius","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1038\/sj.mt.6300363_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(03)01139-2","article-title":"Why did p53 gene therapy fail in ovarian cancer?","volume":"4","author":"Zeimet","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1038\/sj.mt.6300363_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.cgt.7700472","article-title":"A phase I\/II trial of rAd\/p53 (SCH 58500) gene replacement in recurrent ovarian cancer","volume":"9","author":"Buller","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/sj.mt.6300363_bib8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.gt.3301152","article-title":"Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients","volume":"7","author":"Stallwood","year":"2000","journal-title":"Gene Ther"},{"key":"10.1038\/sj.mt.6300363_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.gt.3301775","article-title":"Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas","volume":"9","author":"Zeimet","year":"2002","journal-title":"Gene Ther"},{"key":"10.1038\/sj.mt.6300363_bib10","first-page":"4323","article-title":"Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro","volume":"6","author":"Kelly","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1038\/sj.mt.6300363_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.bjc.6690657","article-title":"Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours","volume":"81","author":"Thomson","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1038\/sj.mt.6300363_bib12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/sj.gt.3302295","article-title":"Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus","volume":"11","author":"Green","year":"2004","journal-title":"Gene Ther"},{"key":"10.1038\/sj.mt.6300363_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.gt.3301389","article-title":"Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies","volume":"8","author":"Fisher","year":"2001","journal-title":"Gene Ther"},{"key":"10.1038\/sj.mt.6300363_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/10611860400020449","article-title":"Enhanced gene transfer activity of peptide-targeted gene-delivery vectors","volume":"13","author":"Parker","year":"2005","journal-title":"J Drug Target"},{"key":"10.1038\/sj.mt.6300363_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.cgt.7701022","article-title":"Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins","volume":"14","author":"Stevenson","year":"2007","journal-title":"Cancer Gene Ther"},{"issue":"suppl. 1","key":"10.1038\/sj.mt.6300363_bib16","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1002\/jgm.553","article-title":"Adenovirus endocytosis","volume":"6","author":"Meier","year":"2004","journal-title":"J Gene Med"},{"key":"10.1038\/sj.mt.6300363_bib17","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/JVI.79.4.1992-2000.2005","article-title":"Adenovirus protein VI mediates membrane disruption following capsid disassembly","volume":"79","author":"Wiethoff","year":"2005","journal-title":"J Virol"},{"key":"10.1038\/sj.mt.6300363_bib18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/93.18.1375","article-title":"Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells","volume":"93","author":"Alper","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/sj.mt.6300363_bib19","doi-asserted-by":"crossref","first-page":"35000","DOI":"10.1074\/jbc.273.52.35000","article-title":"Endocytosis of functional epidermal growth factor receptor-green fluorescent protein chimera","volume":"273","author":"Carter","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1038\/sj.mt.6300363_bib20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archotol.125.8.856","article-title":"Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma","volume":"125","author":"Blackwell","year":"1999","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1038\/sj.mt.6300363_bib21","first-page":"641","article-title":"Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids","volume":"7","author":"Grill","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1038\/sj.mt.6300363_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/0008-5472.CAN-05-2691","article-title":"Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin","volume":"66","author":"Lockley","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/sj.mt.6300363_bib23","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/1097-0142(195611\/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7","article-title":"Studies on the use of viruses in the treatment of carcinoma of the cervix","volume":"9","author":"Smith","year":"1956","journal-title":"Cancer"},{"key":"10.1038\/sj.mt.6300363_bib24","first-page":"49","article-title":"Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report","volume":"10","author":"Georgiades","year":"1959","journal-title":"Biul Inst Med Morsk Gdansk"},{"key":"10.1038\/sj.mt.6300363_bib25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/10611860701501014","article-title":"Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy","volume":"15","author":"Fisher","year":"2007","journal-title":"J Drug Target"},{"key":"10.1038\/sj.mt.6300363_bib26","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.20.6.1562","article-title":"Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent\/refractory epithelial ovarian cancer","volume":"20","author":"Vasey","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1038\/sj.mt.6300363_bib27","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/j.1460-2075.1996.tb00525.x","article-title":"The role of the adenovirus protease on virus entry into cells","volume":"15","author":"Greber","year":"1996","journal-title":"EMBO J"},{"key":"10.1038\/sj.mt.6300363_bib28","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.gt.3301319","article-title":"Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status","volume":"7","author":"Heise","year":"2000","journal-title":"Gene Ther"},{"key":"10.1038\/sj.mt.6300363_bib29","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1038\/sj.mt.6300363_bib30","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2004.12.040","article-title":"Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial","volume":"22","author":"Xiong","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1038\/sj.mt.6300363_bib31","first-page":"6377","article-title":"Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule","volume":"61","author":"Hemminki","year":"2001","journal-title":"Cancer Res"},{"key":"10.1038\/sj.mt.6300363_bib32","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/hum.2005.16.1439","article-title":"Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone","volume":"16","author":"De Geest","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1038\/sj.mt.6300363_bib33","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.reactfunctpolym.2006.05.002","article-title":"Synthesis and properties of new N-(2-hydroxypropyl)-methacylamide copolymers containing thiazolidine-2-thione reactive group","volume":"66","author":"Subr","year":"2006","journal-title":"Reactive and Functional Polymers"},{"key":"10.1038\/sj.mt.6300363_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/abio.1997.2177","article-title":"Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation","volume":"249","author":"Singer","year":"1997","journal-title":"Anal Biochem"},{"key":"10.1038\/sj.mt.6300363_bib35","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1128\/JVI.70.11.7498-7509.1996","article-title":"Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy","volume":"70","author":"Mittereder","year":"1996","journal-title":"J Virol"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616313892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616313892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T10:05:47Z","timestamp":1588154747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616313892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S1525001616313892"],"URL":"https:\/\/doi.org\/10.1038\/sj.mt.6300363","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}